ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. have entered into a second assay development agreement to develop, optimise and validate a molecular diagnostic test for Dengue virus (DENV) detection on ReadyGo’s off-grid isothermal diagnostic platform, Geo. The partnership is hoping to play a crucial role in the detection of DENV within near patient settings, which would greatly improve patient management and outcome.
Dengue fever is a viral infection caused by DENV which is spread by mosquitoes. It is a significant public health concern in many tropical and subtropical regions of the world, with up to 400 million people being infected each year, of which approximately 100 million people get sick and 40,000 die from the severe form of the virus, known as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Symptoms include high fever, severe headache, joint and muscle pain, rash and mild bleeding.
The Geo platform will allow rapid results in any location in under 30 minutes, which will provide early diagnosis and timely medical intervention, preventing complications associated with severe dengue. Ben Cobb, CEO of ReadyGo Diagnostics, said: “We are delighted to further our collaboration with Gemina to develop a sensitive and quick DENV diagnostic assay. There is a pressing need for a decentralised test, particularly in resource-constrained areas. ReadyGo has some really innovative technology and we are fully dedicated to becoming the preferred development partner for companies striving to design straightforward and economical molecular diagnostic solutions across various contexts.”
Brian Firth, CEO of Gemina, added: “At Gemina Labs, our mission is to develop enhanced diagnostic tests for infectious diseases. Our primary focus lies in creating efficient tests that can be utilized at the forefront of patient care, whether that involves field settings, home environments, or primary clinics. This is why ReadyGo’s platform, Geo, has left a strong impression on us – particularly in its potential applications for diagnosing and managing dengue fever. I hold a strong belief that through our partnership with ReadyGo, we’ll have the capability to produce a rapid and precise solution for detecting DENV, ultimately leading to tangible improvements in patient outcomes.”
Financial terms of the agreement have not been disclosed.
ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. have entered into a second assay development agreement to develop a molecular diagnostic test for the detection of Dengue virus (DENV) on ReadyGo’s off-grid isothermal diagnostic platform, Geo. This partnership aims to play a key role in the detection of DENV within near patient settings, allowing timely medical intervention and improved patient outcomes.
Dengue fever is a mosquito-borne, single positive-stranded RNA virus of the family Flaviviridae; genus Flavivirus, with four serotypes that can cause a range of health issues. It is a significant public health concern in many tropical and subtropical regions of the world, with up to 400 million people being infected each year, of which approximately 100 million people get sick and 40,000 die from severe forms of the virus such as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Symptoms of dengue fever include high fever, severe headache (usually behind the eyes), joint and muscle pain, rash, and mild bleeding (such as nose or gum bleeding).
The Geo platform will provide rapid results in any location in under 30 minutes, allowing deployment outside of the laboratory which will support early diagnosis and prompt medical care to reduce the risk of complications associated with severe dengue. Ben Cobb, CEO of ReadyGo Diagnostics, stated: “We are delighted to further our collaboration with Gemina to develop a sensitive and quick DENV diagnostic assay. There is a pressing need for a decentralised test, particularly in resource-constrained areas. ReadyGo has some really innovative technology and we are fully dedicated to becoming the preferred development partner for companies striving to design straightforward and economical molecular diagnostic solutions across various contexts.”
Brian Firth, CEO of Gemina, added: “At Gemina Labs, our mission is to develop enhanced diagnostic tests for infectious diseases. Our primary focus lies in creating efficient tests that can be utilized at the forefront of patient care, whether that involves field settings, home environments, or primary clinics. This is why ReadyGo’s platform, Geo, has left a strong impression on us – particularly in its potential applications for diagnosing and managing dengue fever. I hold a strong belief that through our partnership with ReadyGo, we’ll have the capability to produce a rapid and precise solution for detecting DENV, ultimately leading to tangible improvements in patient outcomes.”
ReadyGo Diagnostics Ltd. and Gemina Laboratories Ltd. have entered into a second assay development agreement to create a molecular diagnostic test for the
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.